• Publications
  • Influence
Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
TLDR
Amisulpride is characterized as a specific dopamine receptor antagonist with high and similar affinity for the dopamine D2 and D3 receptor with a degree of limbic selectivity and a preferential effect, at low doses, on dopamine D 2/D3 autoreceptors. Expand
SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia
TLDR
Findings characterize SSR180711 as a promising new agent for the treatment of cognitive symptoms of schizophrenia and the antidepressant-like properties of SSR 180711 are of added interest, considering the high prevalence of depressive symptoms in schizophrenic patients. Expand
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
TLDR
In patients who had discontinued L-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. Expand
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
TLDR
Findings point to a role for vasopressin in the modulation of emotional processes via the V1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders. Expand
SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile
TLDR
It is demonstrated that SSR180711 is a selective and partial agonist at human, rat and mouse α7 n-AChRs, increasing glutamatergic neurotransmission, ACh release and LTP in the hippocampus. Expand
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
TLDR
Findings point further to a role for the endocannabinoid system in the modulation of emotional processes and suggest that it may be primarily involved in the adaptive responses to unavoidable stressful stimuli. Expand
Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic
TLDR
SSR504734 is a potent and selective GlyT1 inhibitor, exhibiting activity in schizophrenia, anxiety and depression models, and is expected to be efficacious not only against positive but also negative symptoms, cognitive deficits, and comorbid depression/anxiety states. Expand
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a
TLDR
SSR149415 is a potent, selective, and orally active V1b receptor antagonist and deserves to be clinically investigated in the field of stress and anxiety. Expand
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective
TLDR
Results indicate that SSR125543A shows good activity in acute and chronic tests of unavoidable stress exposure, suggesting that it may have a potential in the treatment of depression and some forms of anxiety disorders. Expand
Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
TLDR
The results demonstrate that rimonabant plays a hepatoprotective role and suggest that this CB1 receptor antagonist potentially has clinical applications in the treatment of obesity‐associated liver diseases and related features of metabolic syndrome. Expand
...
1
2
3
4
5
...